Articles & Video
China Bio: Change and opportunity are constant
Rapid, unrelenting changes are altering China’s biotech landscape in 2020. Speakers at China Showcase in San Francisco last month focused on the fundamentals of this maturing market.
What's shaping the future of biotech?
Could the November presidential election impact drug prices? What does the investment landscape look like for this year? Download the free article pack to discover how financial and biotech experts tackled these questions and many more at Biotech Showcase™ and Digital Medicine & Medtech Showcase.
Networking your way to the top, whether in North Face or Brooks Brothers
Timmerman selected Mount Kilimanjaro, a more achievable trek for most climbers, for his next philanthropic adventure, and invited members of the biotech community and employees of Fred Hutch to join him. On January 14, 2019, Timmerman will do a presentation on the Climb to Fight Cancer at Biotech Showcase™, from 4:15–5 pm, at the Parc 55 San Francisco Hotel.
The Power of Presenting at Biotech Showcase
Informa Pharma Intelligence analysts took a deep dive into what has happened to companies who have presented at Biotech Showcase. Since 2015, over 250 companies that have presented at Biotech Showcase have generated deals worth over $61bn.
Giving a Pharma Giant a Tech Startup Makeover
This shows how we’re using data and digital to reimagining medicine. If successful, this could open up the entire area of digital therapeutics.
Biotech VC Down 20% in US as Policies Drive Away Foreign Investors, BIO Says
Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
Investor Survey: US Leads Global Healthcare Innovation, but China to Catch Up by 2025
According to a survey of 53 China-focused life science investors, 79% of the respondents believe the US is the current global leader in innovation for life science while only 15% picked China. But fast forward six years to expectations for 2025, the vote was split evenly between the two countries at about 48% each, a big turnaround.
Antimicrobial resistance: Workable business models for AMR innovation
Many antibiotics are no longer effective. Every year, an estimated 33,000 people die from resistant agents in the EU. More and more multiresistant strains arise across the globe and the list of last resort antibiotics gets smaller, which is why the United Nations has named antibiotic resistance the "biggest and most urgent global health threat."
New players to step into the AMR field
Despite challenging market conditions public and private stakeholders around the globe show promising action to advance drug development in the fight against antimicrobial resistance. Even new players are entering the field.
Digital Health: Advancing innovation through technology and strategic partnerships
Insights from investors, biopharma leaders and digital health executives on how to navigate the digital health sector as it transforms every aspect of the pharmaceutical value chain.
Pharma embraces biopartnering at BIO-Europe to address its innovation deficit
Big pharma’s appetite for early preclinical assets continues to grow and now represents the development phase with the most deals and largest total deal value. Consequently, an increasing number of academic institutions are taking the opportunity to showcase their efforts in the academic track at BIO-Europe.
Just do it. Nike showcases Barcelona’s Startup Slam winner
What are the winners of the past BIO-Europe Spring and BIO-Europe's Startup Slam doing? Catch up with some of them and their most recent successes. Starting with Peptomyc’s co-founders Laura Soucek and Marie-Eve Beaulieu.